Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer

Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700) is engaging with a USA based biotech company to
become a contract manufacturer for a new type of cancer treatment and
is creating a new production plant for this purpose at its
Braunschweig location with financial support provided by the
customer.

The cooperation enfolds a brand-new radiotherapy product,
currently in development, aimed at treating pancreatic cancer by
means of radioimmunotherapy. This form of treatment combines all the
benefits of immunotherapy with those offered by radiotherapy.
Antibodies transport the source of radiation directly to the cancer
cells, enabling the precise deployment of radiation to fight the
tumor. Eckert & Ziegler was hand picked as an exclusive contract
manufacturer for the clinical phase III trial of the new radiotherapy
product in Europe. At its production location in Braunschweig, the
radiation specialist couples the antibodies with the radioisotope
Yttrium-90 to produce the final active agent. Some 110,000 people are
diagnosed with pancreatic cancer every year in Europe alone.
Pancreatic cancer is considered to be one of the most aggressive and
therapy-resistant forms of cancer.

"We are delighted to have been selected as a strategic partner for
this interesting and hugely important product," says Dr. André Heß,
Member of the Executive Board of Eckert & Ziegler and Head of the
Radiopharma Segment. "The decision demonstrates how well our
Radiopharma Segment, restructured a number of years ago, can support
the requirements of innovative developers by the provision of
exceptional radiochemical and technical expertise that enables
approved pharmaceutical manufacturing, all of which is backed-up by a
world-wide logistics infrastructure. We anticipate a large number of
similar projects over the coming years and are confident of
reinforcing our position as the first port of call for the
co-operative development of nuclear medical compounds around the
world."

Eckert & Ziegler has several radiopharma production locations in
Germany and besides fluorine-18-based radiodiagnostics for nuclear
imaging (PET), also distributes the approved product Yttriga®, a
precursor to countless radiotherapy products. Globally, Eckert &
Ziegler also provides nuclear medicine institutions with synthesis
technology and Gallium-68 radionuclide generators.

About Eckert & Ziegler

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), with more than 700 employees, is one of the world's
largest providers of isotope technology for radiation therapy and
nuclear medicine.

Contributing to saving lives

Contact:
Eckert & Ziegler AG,
Karolin Riehle, Investor Relations & PR,
Robert- Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 941084-138, Fax-112,
E-Mail: karolin.riehle@ezag.de, www.ezag.com